- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00706615
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated metastatic breast cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
Primary
- Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with metastatic breast cancer.
- Identify a tolerable, immunologically active dose level of this vaccine in these patients.
Secondary
- Evaluate the immune function in these patients before and after treatment with this vaccine.
OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.
After completion of study treatment, patients are followed monthly for 9 months.
Type d'étude
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the breast with marrow involvement.
- Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29
- Stable disease (defined as fluctuation of <50U in CA15-3 or CA27-29 value) for at least 3 months while either on no breast-cancer therapy or while on current therapy (Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or trastuzumab chemotherapy is not allowed)
- ability to understand the risks, benefits, and procedures and provide written informed consent.
- less than 28 days prior to enrollment since last surgery and/or radiation therapy.
- performance status <=2 on the ECOG performance scale and life expectancy of greater than 12 months
- NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is abnormal, patient must have an echocardiogram showing a left ventricular ejection fraction greater than the lower limits of normal.
- patients who do not have radiographically assessable locally recurrent or metastatic disease are eligible if they 1) had radiographic or biopsy proven locally recurrent or metastatic breast cancer in the past and 2) currently (at study entry) have an elevated serum MUC-1 level (as measured by CA 15-3 or CA 27-29).
- Acceptable pulmonary function. if questionable, a pulmonary function test will be performed.
- negative serology for hepatitis B, C and HIV.
- red cell mean corpuscular volume >- 80 cu. mm, hemoglobin >- 8g/dl, platelet count >- 100,000/dl: AST, ALT, LDH <-2 times the Upper limit of normal
- Serum creatinine < 1.6 mg/dL
- for women with child bearing potential, Negative urine pregnancy test within 7 days of registration and willingness to use an approved contraceptive method while participating in this trial.
Exclusion Criteria:
- history of bronchospasm or asthma requiring inhaled or oral steroid treatment
- Normal MUC-1 (CA 15-3 or CA 27-29)
- treatment with steroid or other immunosuppressive medication (for any condition ) within 30 days of trial registration.
- history of any autoimmune disease (e.g., lupus, rheumatoid arthritis, or psoriasis)
- uncontrolled diabetes mellitus
- unable or unwilling to undergo repeated clinical evaluations and other diagnostic procedures or unable to sign an informed consent.
- history of other malignancies, except squamous cell or basal cell carcinoma of the skin or cervical carcinoma in situ.
- Concurrent systemic chemotherapy (tamoxifen, aromatase inhibitors, fulvestrant, trastuzumab and biophosphonates are allowed if started more than 3 months prior to trial registration with evidence of stable disease as defined above. Chemotherapy must have stopped 3 months prior to enrolling in this trial).
- history of ornithine transcarbamylase deficiency
- any acute or chronic viral, bacterial, or fungal infection requiring specific therapy, unless acute therapy was completed within the past 14 days
- No underlying conditions that would contraindicate therapy with study treatment ( or allergies to reagents used in this study)
- history of organ transplant or allogeneic bone marrow transplant
- life threatening or organ-threatening disease expected to require conventional therapy within 4 months.
- pregnant or nursing females.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
Characterize the safety profile of the Ad-sig-hMUC-1/ecdCD40L vector vaccine
|
Identification of a tolerable, immunologically active dose level
|
Mesures de résultats secondaires
Mesure des résultats |
---|
Assess efficacy based on serum MUC-1 level
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Sara Hurvitz, MD, Jonsson Comprehensive Cancer Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000599060
- UCLA-07-05-056
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur Ad-sig-hMUC-1/ecdCD40L vaccine
-
Singapore Clinical Research InstituteClinDatrix, Inc.; MicroVAX, LLCInconnueCancers épithéliaux du poumon, du sein, de l'ovaire, de la prostate et du côlonSingapour
-
Sun Yat-sen UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Zhujiang Hospital; Guangzhou...Pas encore de recrutement